Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies
Year: 2026
Type: preprint
Abstract: Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo . Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.
Authors: Cao Cuong Le, Jinsheng Weng, Jingwei Liu, Federico Mario Aletti, Xiaoyun Cheng, Yongfu Tang, Sridevi Patchva, Matthew Richard, Maya Balakumaran, Mario Marques-Piubelli, Luisa Solis, Wei Lu, Chun-Yen Lin, Fuliang Chu, Jingjing Cao, Abdur Rehman, Kamini Singh, Owhofasa Agbedia, Sushanth Gouni, Karan Chohan, Faezeh Darbaniyan, Selin Kolsuz, Kumudha Balakrishnan, Neeraj Saini, Michael R. Green, Christopher R Flowers, Swaminathan P. Iyer, Francisco Vega, Sattva S Neelapu
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7233943152
